Key result
Post-PCI µQFR ≤ 0.86 was associated with a 2.47-fold higher risk of 18-month major adverse cardiovascular events compared to µQFR > 0.86 after chronic total occlusion percutaneous coronary intervention.
Why the study?
The association between post-PCI Murray law-based quantitative flow ratio and major adverse cardiovascular events in CTO patients remains unclear.
Does a low post-PCI Murray law-based quantitative flow ratio (μQFR ≤ 0.86) predict increased risk of MACE in patients undergoing PCI for chronic total occlusion?
Cohort (n=120)
No
Does a low post-PCI Murray law-based quantitative flow ratio (μQFR ≤ 0.86) predict increased risk of MACE in patients undergoing PCI for chronic total occlusion?
Answers are grounded in this paper and cite their sources.
A post-PCI μQFR ≤ 0.86 identifies patients at higher risk for MACE, primarily driven by repeat revascularization, after technically successful CTO PCI.
Residual functional impairment after successful chronic total occlusion (CTO) percutaneous coronary intervention (PCI) may increase the risk of adverse events. The Murray law-based quantitative flow ratio (μQFR) is an angiography-derived physiological index for post-PCI assessment, but its association with major adverse cardiovascular events (MACE) in CTO patients remains unclear. This study retrospectively analyzed 120 patients undergoing PCI for CTO. An exploratory cutoff of 0.86 for post-PCI μQFR was identified by selecting the threshold that maximized the log-rank statistic for MACE, and patients were classified into post-PCI μQFR > 0.86 and ≤ 0.86 groups. Cox regression, receiver operating characteristic (ROC) curve analysis, and sensitivity analyses were performed to evaluate the association between post-PCI μQFR and MACE. During a median follow-up of 540 days (interquartile range [IQR], 389.5–540 days), 44 patients (36.7%) developed MACE. The composite endpoint was predominantly driven by repeat revascularization: 42 of the 44 patients with MACE (95.5%) underwent repeat revascularization, whereas no all-cause deaths and only two non-fatal myocardial infarctions occurred. Patients with post-PCI μQFR ≤ 0.86 had a significantly higher incidence of MACE than those with μQFR > 0.86 (71.4% vs. 26.1%, P < 0.001). In multivariable Cox regression analysis, post-PCI μQFR ≤ 0.86 was associated with a 2.47-fold higher risk of MACE than a post-PCI μQFR > 0.86 (hazard ratio [HR] 2.47, 95% confidence interval [CI] 1.29–4.71, P = 0.006). Post-PCI μQFR yielded an AUC of 0.734 (95% CI 0.639–0.828) for MACE. Sensitivity analyses indicated that the results were robust. Post-PCI µQFR ≤ 0.86 was associated with a higher 18-month risk of MACE after CTO PCI, with repeat revascularization accounting for most events. Low post-PCI µQFR may help identify residual angiographic or physiological impairment after technically successful CTO PCI.
No takes yet. Share an insight, caveat, or question.
Sha et al. (2026) conducted a cohort in Chronic total occlusion (CTO) (n=120). Post-PCI μQFR ≤ 0.86 vs. Post-PCI μQFR > 0.86 was evaluated on 18-month major adverse cardiovascular events (MACE) (HR 2.47, 95% CI 1.29-4.71, p=0.006). Post-PCI µQFR ≤ 0.86 was associated with a 2.47-fold higher risk of 18-month major adverse cardiovascular events compared to µQFR > 0.86 after chronic total occlusion percutaneous coronary intervention.
Synapse has enriched 10 related papers. Consider them for comparative context: